If you think your portfolio is volatile, wait till you meet Sadhana Nitro Chem Ltd — a company where revenues are collapsing, losses are exploding, promoters are playing musical chairs with shares, and lenders are already calling it a defaulter.
Let’s set the tone:
Quarterly revenue fell -73% YoY
Quarterly loss: ₹25 Cr (on ₹9.7 Cr sales — yes, loss > revenue)
And just when you thought things couldn’t get more entertaining, the company issued billions of new shares at ₹1, massively diluting existing shareholders.
So the real question is: Is this a deep-value turnaround… or a live-action remake of Scam 1992 (Chemical Edition)?
Let’s investigate like a forensic auditor with a sense of humour.
2. Introduction – A 50-Year Old Company Acting Like a Startup Gone Rogue
Founded in 1973, this company has survived:
License Raj
Economic liberalization
Multiple commodity cycles
But somehow… it is now struggling in 2026.
The irony? This is a specialty chemical company, a sector that has been one of India’s biggest wealth creators.
While peers were minting money exporting chemicals globally, Sadhana Nitro Chem was busy:
Delaying loan payments
Getting downgraded to default
Watching its margins collapse
Even the credit rating agency politely said: “Sir… you are not paying EMIs.”
And then comes the cherry on top:
Fire incident
PAP plant shutdown
Chinese dumping
Regulatory inspections
At this point, this is not a business cycle… This is a full Bollywood tragedy with interval pending.
Question for you: If a chemical company cannot benefit from a chemical boom… what exactly is it doing?
3. Business Model – WTF Do They Even Do?
On paper, the business looks solid:
They manufacture:
Nitrobenzene
Meta Amino Phenol (MAP)
Para Amino Phenol (PAP)
ODB2 (used in thermal paper)
Applications:
Pharma (Paracetamol)
Agro chemicals
Dyes
Aerospace
Cosmetics
Translation for lazy investors: They make intermediate chemicals that go into everything from medicines to receipts at your local kirana store.
Sounds great, right?
Now reality check:
PAP (key product) → Not operational for most of FY25
Chinese imports → Crushed pricing
Inventory piling → Money stuck
Receivables → Customers behaving like “bhai kal deta hoon”
So technically, they make chemicals. Practically, they are running a working capital museum.
Question: If your biggest product isn’t even running… are you a chemical company or a land bank?
4. Financials Overview – Numbers That Need Therapy
Result Type Detected: Quarterly Results (Q3 FY26) So EPS annualisation rule: multiply by 4.
Financial Comparison Table
Metric
Q3 FY26
Q3 FY25
Q2 FY26
YoY %
QoQ %
Revenue (₹ Cr)
10
37
3
-73%
+233%
EBITDA (₹ Cr)
-15
11
-17
NM
Improvement
PAT (₹ Cr)
-25
3
-26
-1074%
Slight better
EPS (₹)
-0.08
0.01
-0.09
Collapse
Slight better
Data Source:
Annualised EPS
Latest EPS: -0.08
Annualised EPS: -0.32
So P/E? Not applicable. You don’t calculate P/E on losses… unless you enjoy self-harm.
Witty observation: Revenue fell like crypto in 2022… But expenses said: “Hum toh full power chalenge.”
5. Valuation Discussion – Fair Value (or Fair Warning?)
